All Title Author
Keywords Abstract


Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells

DOI: 10.3390/ijms11114441

Keywords: Lewis (y) antigen, matrix metalloproteinases, tissue inhibitors of metalloproteinases, invasion

Full-Text   Cite this paper   Add to My Lib

Abstract:

Lewis (y) antigen is a difucosylated oligosaccharide present on the plasma membrane, and its overexpression is frequently found in human cancers and has been shown to be associated with poor prognosis. Our previous studies have shown that Lewis (y) antigen plays a positive role in the process of invasion and metastasis of ovarian cancer cells. However, the mechanisms by which Lewis (y) antigen enhances the invasion and tumor metastasis are still unknown. In this study, we established a stable cell line constitutively expressing Lewis (y) antigen (RMG-1-hFUT) by transfecting the cDNA encoding part of the human α1,2-fucosyltransferase (α1,2-FUT) gene into the ovarian cancer cell line RMG-1, and investigated whether Lewis (y) antigen regulates the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9, and tissue inhibitors of metalloproteinases (TIMP-1) and TIMP-2. We found that RMG-1-hFUT cells exhibited higher invasive capacities than their control cells. In addition, expression of TIMP-1 and TIMP-2 was down-regulated and expression of MMP-2 and MMP-9 was up-regulated. Anti-Lewis (y) antigen antibody treatment significantly reversed the expression of TIMP-1, TIMP-2, MMP-2 and MMP-9. Taken together, we provide the first evidence that down-regulation of TIMP-1 and TIMP-2 and up-regulation of MMP-2 and MMP-9 represents one of the mechanisms by which Lewis (y) antigen promotes cell invasion.

References

[1]  Kitamura, K; Stockert, E; Garin-Chesa, P; Welt, S; Lloyd, KO; Armour, KL; Wallace, TP; Harris, WJ; Carr, FJ; Old, LJ. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants. Proc. Natl. Acad. Sci., USA 1994, 91, 12957–12961.
[2]  Hokke, CH; Neeleman, AP; Koeleman, CA; van den Eijnden, DH. Identification of an alpha3-fucosyltransferase and a novel alpha2-fucosyltransferase activity in cercariae of the schistosome Trichobilharzia ocellata: Biosynthesis of the Fucalpha1-->2Fucalpha1-->3[Gal(NAc)beta1-->4]GlcNAc sequence. Glycobiology 1998, 8, 393–406.
[3]  Dettke, M; Palfi, G; Loibner, H. Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J. Leukoc. Biol 2000, 68, 511–514.
[4]  Hellstrom, I; Garrigues, HJ; Garrigues, U; Hellstrom, KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990, 50, 2183–2190.
[5]  Madjd, Z; Parsons, T; Watson, NF; Spendlove, I; Ellis, I; Durrant, LG. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 2005, 7, R780–R787.
[6]  Zhu, LC; Lin, B; Hao, YY; Li, FF; Diao, B; Zhang, SL. Impact of alpha1,2-fucosyl transferase gene transfection on cancer-related gene expression profile of human ovarian cancer cell line RMG-1. Ai Zheng 2008, 27, 934–941.
[7]  Vernon, AE; LaBonne, C. Tumor metastasis: A new twist on epithelial-mesenchymal transitions. Curr. Biol 2004, 14, R719–R721.
[8]  Vazquez-Ortiz, G; Pina-Sanchez, P; Vazquez, K; Duenas, A; Taja, L; Mendoza, P; Garcia, JA; Salcedo, M. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 2005, 5. doi:10.1186/1471-2407-5-68.
[9]  Visse, R; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res 2003, 92, 827–839.
[10]  Talvensaari-Mattila, A; Paakko, P; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 2003, 89, 1270–1275.
[11]  Pellikainen, JM; Ropponen, KM; Kataja, VV; Kellokoski, JK; Eskelinen, MJ; Kosma, VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin. Cancer Res 2004, 10, 7621–7628.
[12]  Kim, MH; Kitson, RP; Albertsson, P; Nannmark, U; Basse, PH; Kuppen, PJ; Hokland, ME; Goldfarb, RH. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J. Immunol 2000, 164, 5883–5889.
[13]  Lu, KV; Jong, KA; Rajasekaran, AK; Cloughesy, TF; Mischel, PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab. Invest 2004, 84, 8–20.
[14]  van den Steen, PE; Dubois, B; Nelissen, I; Rudd, PM; Dwek, RA; Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol 2002, 37, 375–536.
[15]  Chang, C; Werb, Z. The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001, 11, S37–43.
[16]  Yan, LM; Lin, B; Zhu, LC; Hao, YY; Qi, Y; Wang, CZ; Gao, S; Liu, SC; Zhang, SL; Iwamori, M. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie 2010, 92, 852–857.
[17]  Gao, S; Liu, Q; Wang, X; Lin, B; Zhang, S. Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med. Oncol 2010, 27, 960–967.
[18]  Liu, J; Lin, B; Hao, Y; Qi, Y; Zhu, L; Li, F; Liu, D; Cong, J; Zhang, S; Iwamori, M. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J. Exp. Clin. Cancer Res 2009, 28, 154.
[19]  Liu, JJ; Lin, B; Hao, YY; Li, FF; Liu, DW; Qi, Y; Zhu, LC; Zhang, SL; Iwamori, M. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol. Rep 2010, 23, 833–841.
[20]  Redondo-Munoz, J; Ugarte-Berzal, E; Terol, MJ; van den Steen, PE; del Cerro, MH; Roderfeld, M; Roeb, E; Opdenakker, G; García-Marco, JA; García-Pardo, A. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17, 160–172.
[21]  O-Charoenrat, P; Rhys-Evans, P; Modjtahedi, H; Court, W; Box, G; Eccles, S. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int. J. Cancer 2000, 86, 307–317.
[22]  Choi, YA; Lim, HK; Kim, JR; Lee, CH; Kim, YJ; Kang, SS; Baek, SH. Group IB secretory phospholipase A2 promotes matrix metalloproteinase-2-mediated cell migration via the phosphatidylinositol 3-kinase and Akt pathway. J. Biol. Chem 2004, 279, 36579–36585.

Full-Text

comments powered by Disqus